ČESKÁ UROLOGIE / CZECH UROLOGY – 3 / 2020

205 PŘEHLEDOVÝ ČLÁNEK Ces Urol 2020; 24(3): 191–206 Závěrem je vhodné dodat, že všechny v textu uvedené operační metody vedly ke snížení IPSS, IPSS QoL a zvýšení Q max při minimálních změ‑ nách sexuálních funkcí. Nežádoucí účinky byly většinou mírné a přechodné. Až dlouhodobé používání v běžné klinické praxi nám ukáže, zda se některá z hodnocených metod stane součástí standardního algoritmu léčby mužů se středně těžkými až těžkými mikčními potížemi způso‑ benými BHP. LITERATURA 1. Srinivasan A, Wang R. An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Tech‑ niques, Risks, and Efficacy. The world journal of men’s health, 2019. 2. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation‑image‑guided robot‑assisted waterjet ablation of the prostate: initial clinical experience. BJU international. 2016; 117(6): 923–929. 3. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. The Journal of urology. 2017; 197(6): 1565–1572. 4. Gilling P, Barber N, Bidair M, et al. WATER: a double‑blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. The Journal of urology. 2018; 199(5): 1252–1261. 5. Gilling P, Barber N, Bidair M, et al. Two‑Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Advances in therapy. 2019; 36(6): 1326–1336. 6. PhamH, Sharma P. Emerging, newly‑approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. The Canadian journal of urology. 2018; 25(2): 9229. 7. Woo HH, Chin PT, McNicholas, TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, mini‑ mally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU international. 2011; 108(1): 82–88. 8. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two‑year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012; 79(1): 5–11. 9. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral LIFT study. The Canadian journal of urology. 2015; 22(3): 7772–7782. 10. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral LIFT study. The Canadian journal of urology. 2017; 24(3): 8802–8813. 11. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prosta‑ te: 2-year results of the BPH 6 prospective, multicentre, randomized study. BJU international. 2017; 119(5): 767–775. 12. Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. European urology. 2015; 68(4): 643–652. 13. Rukstalis D, Barber NJ, Speakman MJ, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate cancer and prostatic diseases. 2018: 1. 14. Das A, Leong J, Roehrborn C. Office‑based therapies for benign prostatic hyperplasia: a review and update. The Canadian journal of urology. 2019; 26(4S1): 2–7. 15. Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. The Rezūm System – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. The Canadian journal of urology. 2019; 26: 3. 16. Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Therapeutic advances in urology. 2018; 10(11): 327–333. 17. Dixon CM, Cedano ER, Pacik D, et al. Two‑year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Research and reports in urology. 2016; 8: 207.